[Juvenile rheumatoid arthritis].
Yokota
Shumpei
S
Department of Pediatrics, Yokohama City University School of Medicine.
D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000145:classification / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D000068800:Etanercept; D006684:HLA-DR Antigens; D059810:HLA-DR Serological Subtypes; D015804:HLA-DR4 Antigen; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D015850:Interleukin-6; D011379:Prognosis; D019947:Receptors, Interleukin-6 / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology / Q000627:therapeutic use; D012217:Rheumatoid Factor; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D006684:HLA-DR Antigens; D059810:HLA-DR Serological Subtypes; D015804:HLA-DR4 Antigen; C038988:HLA-DR9 antigen; D007074:Immunoglobulin G; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D012217:Rheumatoid Factor; D000069285:Infliximab; D000068800:Etanercept